Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Spencer Trask & Co. launches Signal12 for Dry Eye Disease treatment, led by former Aerie executives, advancing Pro-ocular through trials

Spencer Trask & Co. the advanced technology development firm, announced today the launch of Signal12 Inc. (Signal12), a clinical-stage dry eye company. Signal12 is revolutionizing treatments for Dry Eye Disease (DED) and eliminating the hassle of...

Persist AI and Nivagen partner to develop AI-driven manufacturing for long-acting injectables

Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist's AI-based formulation technology and Nivagen's manufacturing capabilities. The...

Biosyngen's BRG01 gets FDA approval for Phase II clinical trial.

Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI...

Stay Protected

(tetanus, diphtheria and pertussis) and HPV, are known to prevent around 4 million global deaths annually. However, only 1 in 5 adults are up to date on their vaccines, highlighting a critical gap in public health awareness and readiness. Vaccines...

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

whom symptomatic skin involvement interferes with their daily quality of life. LYMPHIR's median time-to-response of only 1.4 months (min, max: 0.7, 5.6) offers many patients rapid skin relief," added Dr. Myron Czuczman, Chief Medical Officer of...

Axion BioSystems extends its agreement with Corning®, granting exclusive rights to distribute its award-winning cell counting device.

powerful device, developed by Axion BioSystems and distributed by Corning, was recently included in the SelectScience® top 10 list of remarkable products advancing life science research. The agreement extends the successful collaboration between...

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

therapies designed to halt fibrosis progression, today announced the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-474, a human IgG1 antibody designed to neutralize EphrinB2 signaling....

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

for exclusive rights in Canada to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionate...

Sensitech acquires Berlinger & Co. to expand life sciences cold chain solutions

Carrier Global Corporation, on behalf of its Sensitech business, a world leader in supply chain visibility, has completed its acquisition of the Monitoring Solutions business of Berlinger & Co. AG, a Swiss family-owned company that specializes in...

Jade Biosciences launches with $80 million to develop transformative autoimmune disease therapies

inflammation and immunology. The company named Andrew King, D.V.M., Ph.D., as Chief Scientific Officer, bringing more than 15 years of leadership experience across biotech and pharmaceutical industries to the organization. Dr. King previously...

Eximia Research Network expands into Virginia by integrating Tidewater Clinical Research

in Women's Health and Ophthalmology with Eximia's extensive clinical trial experience and resources. Since its inception in 1994, Tidewater has led advancements in Women's Health through clinical trials in the Hampton Roads/Eastern Virginia region,...

Inoviv launches MasterKey™, a customizable platform for multiplexed protein assays

Inoviv announces the launch of MasterKey™, which enables researchers to select specific proteins from a comprehensive, pre-characterized catalog of thousands of proteins. This database is built from years of extensive research, utilizing technical...

Clarivate introduces the new OFF-X™ platform for preclinical and clinical safety intelligence

and visualizations, as well as comprehensive range of safety information sources and datasets, including a range of over 15,000 targets and more than 39,000 drugs & biologics, populated with almost 3 million expertly curated safety alerts...

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA – previously referred to as QM1114). RelfydessTM is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines)...

Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients

unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). This chronic inflammatory condition, which affects over 6 million...

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

lipid-lowering therapy. The BROOKLYN trial met its primary endpoint, achieving an LS mean reduction of 36.3% (p < 0.0001) compared to placebo at day 84, which was sustained at day 365 with an LS mean LDL-C reduction of 41.5% (p...

AIM ImmunoTech announces the release of the next CEO Corner segment

the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides an overview of the positive data from the Phase 1 clinical trial investigating an Ampligen-containing chemokine modulation therapy in conjunction with the chemotherapy drug...

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

severe unmet medical needs, announced that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase 1b/2a BGBC016 study confirmed acceptable safety at the highest dose tested in the Phase 1b. As a result, the DSMB also...

Astellas gets positive CHMP opinion for PADCEV™ and KEYTRUDA® combo in advanced bladder cancer.

of PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for...

Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease

a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Sanofi announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-’574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for...